YOLFTbeta
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares

Cuprina Holdings (Cayman) Limited Class A Ordinary Shares

CUPR · NASDAQ · Healthcare / Medical Instruments & Supplies

1.69USD+0.01 (+0.60%)

Price History

Full chart

Market Stats

Previous Close1.68
Open1.72
Day Range1.69 – 1.79
52-Week Range1.45 – 9.60
Volume50.31K
Market Cap13.10M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.43
Dividend Yield0.00%
50-Day Avg2.95
200-Day Avg3.27

About

Cuprina Holdings (Cayman) Limited, a biomedical and biotechnology company, focuses on the development and commercialization of products for the management of chronic wounds. The company manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products used as a biological debridement tool for chronic wounds under the MEDIFLY brand name. It is also developing collagen dressings, including sponges, particles, and hydrogels using bullfrog collagen derived from the valorization of abattoir waste streams; and products using medical leeches for wound treatment. The company was founded in 2019 and is based in Singapore. Cuprina Holdings (Cayman) Limited operates as a subsidiary of Cuprina Holding Pte. Ltd.

Company Details

  • SectorHealthcare
  • IndustryMedical Instruments & Supplies
  • CEOMr. Yong Qi Quek
  • Employees10
  • HeadquartersBlk 1090, Singapore, Singapore, 169201, USA
  • Websitehttps://www.cuprina.com.sg

Leadership

  • Mr. Yong Qi QuekCEO & Director · b. 1995
  • Mr. Tat Jing ChanChief Financial Officer · b. 1993
  • Dr. Ronald ShermanMedical & Scientific Director

Financials

Income Statement

Currency: SGD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue58.50K56.60K100.77K48.32K49.89K
Growth (%)--3.26%+78.05%-52.05%+3.26%
Cost of Revenue35.45K36.62K64.17K51.34K50.54K
Gross Profit23.06K19.98K36.60K-3.02K-645
Gross Margin39.41%35.30%36.32%-6.26%-1.29%
Operating Expense575.81K1.20M1.10M1.64M4.57M
Operating Income-552.75K-1.18M-1.07M-1.65M-4.57M
Operating Margin-944.81%-2077.40%-1060.13%-3404.85%-9154.62%
EBITDA-489.44K-1.06M-994.12K-1.43M-4.56M
EBITDA Margin-836.60%-1865.87%-986.50%-2957.74%-9137.07%
Net Income-519.69K-1.09M-1.12M-1.56M-4.67M
Net Income Margin-888.29%-1933.81%-1110.97%-3229.52%-9366.75%
R&D279.79K292.88K167.73K241.36K226.88K
R&D as % of Total Revenue478.23%517.46%166.45%499.50%454.73%
Interest Expense2.78K2.02K56.59K37.21K14.72K
Interest Expense % of Total Revenue4.76%3.56%56.15%77.01%29.51%

Balance Sheet

Currency: SGD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets953.05K1.44M1.59M1.75M8.50M
Total Liabilities1.64M3.21M4.48M6.20M3.45M
Total Equity-683.52K-1.78M-2.90M-4.46M5.06M
Cash767.29K564.58K35.26K116.47K3.12M
Total Debt170.03K183.63K121.82K254.79K482.72K
Net Debt-597.26K-380.94K86.56K138.32K-2.63M

Cash Flow

Currency: SGD2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-221.86K-1.85M-1.54M-1.24M-9.13M
Investing Cash Flow-2.86K-31.28K-67.98K-21.88K-58.23K
Financing Cash Flow991.39K1.68M1.08M1.34M12.23M
Capital Expenditure2.86K16.05K67.98K21.88K58.23K
Free Cash Flow-224.72K-1.87M-1.61M-1.26M-9.19M
FCF to OCF101.29%100.87%104.41%101.77%100.64%

Earnings

Report DateDec 6, 2024May 14, 2025Dec 9, 2025
EPS Estimate0.000.000.00
EPS Actual-0.04-0.05-0.10
Surprise---
Timing---

Key Statistics & Ratios

Market Cap13.10M
Enterprise Value11.24M
Trailing P/E0.00
Forward P/E0.00
Price / Sales262.50
Price / Book3.36
EPS-1.43
Book Value1.47
Revenue (TTM)49.89K
Gross Profit (TTM)-645
EBITDA-4.79M
Profit Margin0.00%
Operating Margin-10568.35%
Return on Equity-1569.06%
Return on Assets-58.90%
Shares Outstanding5.24M
Shares Float2.01M
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
0.89%
Insiders
0.00%
Retail / Other
99.11%

Top Institutional Holders

  • XTX Topco Ltd
    35.46K0.17%
  • UBS Group AG
    3630.00%
  • Prospect Financial Group LLC
    00.00%
  • TWO SIGMA SECURITIES, LLC
    00.00%
  • Citadel Advisors Llc
    00.00%

Top Fund Holders

  • Fidelity Nasdaq Composite Index
    2010.01%

Stock Splits

  • May 27, 20261:8